Patents by Inventor Jean Gudas

Jean Gudas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20160256563
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 15, 2016
    Publication date: September 8, 2016
    Inventors: Michael TORGOV, Robert Kendall MORRISON, Aya JAKOBOVITS, Jean GUDAS, Zili AN
  • Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9314538
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 19, 2016
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
    Patent number: 9308278
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 12, 2016
    Assignee: Agensys, Inc.
    Inventors: Michael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
  • NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS
    Publication number: 20160090411
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Application
    Filed: February 2, 2015
    Publication date: March 31, 2016
    Inventors: Aya JAKOBOVITS, Robert Kendall MORRISON, Arthur B. RAITANO, Pia M. CHALLITA-EID, Juan J. PEREZ-VILLAR, Karen Jane Meyrick MORRISON, Mary FARIS, Wangmao GE, Jean GUDAS, Steven B. KANNER
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20150306245
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: July 13, 2015
    Publication date: October 29, 2015
    Applicants: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS
    Publication number: 20150239986
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
    Type: Application
    Filed: January 23, 2015
    Publication date: August 27, 2015
    Applicant: AGENSYS, INC.
    Inventors: Aya JAKOBOVITS, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9078931
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 14, 2015
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 9062113
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: June 23, 2015
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 9029516
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: May 12, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 9023605
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: May 5, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8951744
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 10, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20140194601
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 10, 2014
    Applicant: AGENSYS, INC.
    Inventors: Michael TORGOV, Robert Kendall MORRISON, Aya JAKOBOVITS, Jean GUDAS, Zili AN
  • NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS
    Publication number: 20140051145
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: February 20, 2014
    Applicant: Agensys, Inc.
    Inventors: Aya JAKOBOVITS, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS
    Publication number: 20140051096
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: February 20, 2014
    Applicant: Agensys, Inc.
    Inventors: Aya JAKOBOVITS, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 8637642
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: January 28, 2014
    Assignees: Seattle Genetics, Inc., Agensys, Inc.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
    Patent number: 8609092
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: December 17, 2013
    Assignee: Agensys, Inc.
    Inventors: Michael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Publication number: 20130280163
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
    Type: Application
    Filed: August 12, 2011
    Publication date: October 24, 2013
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • ANTIBODIES THAT BIND TO PSCA PROTEINS FOR DIAGNOSIS OF CANCER
    Publication number: 20130041138
    Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Application
    Filed: September 28, 2012
    Publication date: February 14, 2013
    Inventors: Jean GUDAS, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
  • Antibodies and related molecules that bind to 161P2F10B proteins
    Patent number: 8350009
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: January 8, 2013
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Jean Gudas